"Pentoxifylline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production.
| Descriptor ID |
D010431
|
| MeSH Number(s) |
D03.633.100.759.758.824.651.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pentoxifylline".
Below are MeSH descriptors whose meaning is more specific than "Pentoxifylline".
This graph shows the total number of publications written about "Pentoxifylline" by people in this website by year, and whether "Pentoxifylline" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Pentoxifylline" by people in Profiles.
-
The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study. PLoS Negl Trop Dis. 2021 07; 15(7):e0009635.
-
Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support. Clin Respir J. 2021 Jul; 15(7):843-846.
-
Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. Int Immunopharmacol. 2021 Jan; 90:107209.
-
Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019. Med Princ Pract. 2021; 30(1):98-100.
-
Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. Eur J Pharmacol. 2020 Nov 15; 887:173561.
-
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. Pharmacol Res Perspect. 2020 08; 8(4):e00631.
-
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. Med Hypotheses. 2020 Oct; 143:110051.
-
Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2. Eur Rev Med Pharmacol Sci. 2020 07; 24(13):7494-7496.
-
COVID-19: Pentoxifylline as a potential adjuvant treatment. Int J Clin Pharmacol Ther. 2020 Jul; 58(7):406-407.
-
Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatol Ther. 2020 Jul; 33(4):e13733.